The AGITG Annual Scientific Meeting is widely known throughout Australasia as the premier meeting in the gastro-intestinal (GI) cancer space. The three day meeting provides gastro-intestinal cancer clinicians, researchers and allied health specialists with the opportunity to present their research and discuss current challenges and innovations, as well as to hear from international and local leaders on the latest in research and treatments. The exchange of knowledge and expertise is strongly encouraged in our friendly and collegiate meeting environment. The meeting also provides an opportunity for involvement of health professionals in the scientific activities of the AGITG.

The program structure consists of three days of dedicated program which include keynote sessions featuring international guest speakers, plenary and symposia sessions, trials presentations, poster session, new concepts symposium and workshops. On Thursday 5 October, the AGITG program will be combined with the Australia and New Zealand Gastric and Oesophageal Surgery Association (ANZGOSA) Annual Meeting.

We invite you join us in Cairns for the 19th AGITG Annual Scientific Meeting from 4-6 October 2017.

Professor Eva Segelov
AGITG Annual Scientific Meeting Convenor

Mr Russell Conley
AGITG Chief Executive Officer
Dr. Thierry Alcindor  
*McGill University*

Dr. Thierry Alcindor was born and raised in Port-au-Prince, Haiti. After obtaining his medical degree at Université d'État d’Haïti, he trained in Internal Medicine and Hematology/Oncology at Yale-New Haven Medical Center and Tufts-New England Medical Center, respectively, in the USA. He also holds a Master’s degree in Experimental Therapeutics from the University of Oxford (UK.)

Currently Associate Professor of Oncology and Medicine at McGill University, and Associate Director for Clinical Trials in Oncology at the Center for Innovative Medicine, McGill University Health Centre in Montreal (Canada), he focuses his clinical and research efforts on the care of patients with digestive cancers and sarcomas.

Dr. Alcindor’s clinical research portfolio includes investigator-initiated studies, as well as trials with pharmaceutical companies and oncology cooperative groups. He is co-chair of the Sarcoma Disease Site Committee of the Canadian Cancer Trials Group (CCTG) and a key member of its Gastrointestinal Disease Site Committee as well. In both capacities, he has led several studies as a national principal investigator in Canada. He has authored or co-authored more than 80 peer-reviewed papers, abstracts and book chapters in his areas of expertise.

---

Professor John Bridgewater  
*UCL Cancer Institute, London*

After qualifying in medicine and surgery in 1986, Professor Bridgewater specialised in medical oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals. He undertook a PhD in gene therapy at the Institute of Cancer Research, and subsequently took a senior lecturer position in medical oncology at UCL in 1999.

Professor Bridgewater led the National Cancer Research Institute (NCRI) subgroup in hepatobiliary malignancy, focussing on clinical and translational research. He has contributed to landmark studies in gastrointestinal (GI) malignancy and is chief and co-chief investigator on a number of lead studies in the NCRI upper-GI research portfolio. He is senior author on the BILCAP and ABC-02 studies that have defined the management of biliary tract cancer in the adjuvant and advanced settings respectively. He was a lead investigator on the New EPOC study and has helped develop the portfolios of the colorectal and pancreatic subgroups.

Professor Bridgewater serves on several research committees including the Clinical Trials Advisory and Awards Committee, and the National Institute for Health and Care Excellence committee. He also leads the clinical service for CUP in the Integrated London Cancer Consortium.

---

Dr. Ian Chau  
*Royal Marsden Hospital*

Dr Ian Chau holds the position of consultant medical oncologist within the Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and honorary senior lecturer at the Institute of Cancer Research, London & Surrey, UK.

He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital.

His main research interests are clinical trials and translational research in gastrointestinal cancers and lymphoma. He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways.

He serves or has served on American Society of Clinical Oncology (ASCO) Scientific Program Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups.

He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials.

He has given invited lectures in over 30 countries. He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology and other leading oncology/biomedical journals.

---

We hope to see you in Cairns this October. www.agitg.org.au
We hope to see you in Cairns this October. www.agitg.org.au

**Professor Karyn Goodman**  
*University of Colorado*

Dr. Karyn Goodman is a board-certified radiation oncologist specializing in cancers of the gastrointestinal tract, including malignancies of the esophagus, stomach, pancreas, and liver as well as colorectal and anal cancers. She recently joined the University of Colorado as a Professor in the Department of Radiation Oncology. Dr. Goodman moved to University of Colorado Cancer Center from the Memorial Sloan-Kettering Cancer Center in New York where she had been a faculty member for over eight years. Her initial faculty position was in the Department of Radiation Oncology at Stanford University School of Medicine.

Dr. Goodman obtained her undergraduate and medical degrees from Stanford University and spent a year as a Research Fellow at the Division of Reproductive Health of Centers for Disease Control in Atlanta. She completed her residency training in Radiation Oncology at Memorial Sloan-Kettering Cancer Center where she served as Chief Resident. She earned a Masters in Epidemiology at the Harvard School of Public Health in 2006.

Dr. Goodman’s interests include image-guide radiation therapy, stereotactic body radiotherapy, and intensity modulated radiotherapy treatment planning for gastrointestinal cancers with the intent of reducing toxicity and improving results with radiation therapy. She has also focused her research on quality of life and late effects after radiotherapy. In addition to her interest in technical advances in radiation oncology, she is involved in the development of therapeutic protocols combining radiation, chemotherapy, and targeted agents for gastrointestinal cancers. She has been selected for inclusion in Castle Connolly’s list of America’s Top Doctors for several years.

**Professor John V. Reynolds**  
*St. James Hospital and Trinity College, Dublin*

Professor Reynolds is Professor of Clinical Surgery at the St. James’s Hospital and Trinity College Dublin. He is the National Lead for oesophageal and gastric cancer. He is Cancer Lead at St. James’s Hospital and the Trinity School of Medicine, and a Principal Investigator in the Trinity Translational Medicine Institute. He has formerly held Fellowship positions with the University of Pennsylvania and Wistar Institute in Philadelphia and at the Memorial Sloan-Kettering Cancer Centre in New York. He was a Senior Lecturer at St. James’s University Hospital in Leeds (1994-6).

Professor Reynolds has obtained numerous research awards and has published widely in cancer research, with over 250 publications and approximately €5m research grant income. His clinical interest is in diseases of the oesophagus and stomach. His research interest is in four areas: (1) pathogenesis of Barrett’s oesophagus and progression; (2) prediction of response and resistance to chemotherapy and radiation therapy; (3) obesity, altered metabolism, and cancer; (4) malnutrition and peri-operative nutrition.

**Professor Sean Grimmond**  
*University of Melbourne*

Professor Sean Grimmond BSc PhD FFS RCPA obtained his PhD in pathology from the University of Queensland. He is a founding scientific fellow in The Royal College of Pathologists of Australasia. Previous appointments include the chair of medical genomics at the University of Glasgow, co-director of the Scottish Genomes Partnership, a professor of genetics at the University of Queensland, and founding director of the Queensland Centre for Medical Genomics.

Over the past 8 years, Sean has pioneered whole-genome and transcriptome analysis of cancer patients, led Australia’s International Cancer Genome Consortium efforts into pancreatic, neuroendocrine and ovarian cancer, and contributed cohort-based mutational landscape studies in melanoma and oesophageal cancer. These studies have been used to resolve the mutagenic processes, driver mutations, molecular taxonomies, and potential vulnerabilities open to therapeutic exploitation in these cancer types. His current research is firmly focused on real-time omic analysis of recalcitrant cancers, testing the value of personalised therapies, and further cancer genome discovery.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:00</td>
<td><strong>Keynote Breakfast sponsored by Merck</strong></td>
<td>In the pursuit of precision treatment of colorectal cancer, biomarker discovery has had a major impact on selection of therapy. However biomarkers and consensus molecular subtypes still fail to fully inform treatment decisions. Sidedness of primary tumour has emerged as an additional and potent factor in identifying which therapy should be offered to which patient. This plenary will explore data related to confirmed and potential biomarkers, impact of consensus molecular subtypes on therapy, and the role of tumour sidedness and other clinical features in aiding the practising clinician chose the best possible treatment for their patient.</td>
</tr>
<tr>
<td>9:00 - 10:30</td>
<td><strong>AGITG Opening Plenary sponsored by Amgen</strong></td>
<td>The opening plenary will bring three esteemed speakers together to present a forward looking view of the major issues confronting clinicians and patients with GI cancer in the modern era. Why have recent advances in other cancers not been replicated in GI cancer and how can we design trials and therapies to be more effective?</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td><strong>Translational Science Symposium sponsored by Amgen</strong></td>
<td>We are delighted to have four prominent national speakers who are focused on translational research across a range of GI cancers, including neuroendocrine tumours, pancreatic cancer and colorectal carcinoma. This continues the recent AGITG ASM tradition of exploring how we can both develop bench-science into clinical trials, as well as explore how cutting edge translational platforms in Australia can help address key translational questions in locally-led, AGITG trials.</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td><strong>Study Coordinator Forum</strong></td>
<td>Over the years there have been more treatment and trials available for patients with colorectal cancer vs those with oesophaso/gastric cancer. As a result there is less knowledge amongst the nursing and research staff of the aetiology, prognostic factors, treatment options, survival rates and impact on Quality of Life for patients with oesophaso/gastric cancer. This session aims to provide an overview of oesophagogastrectomy cancer with an emphasis on the use of new targeted therapies in a changing clinical trial environment and the impact these new treatments have on overall quality of life.</td>
</tr>
<tr>
<td>14:00 - 16:15</td>
<td><strong>Trial Session: Colorectal &amp; Anal Cancer Trials</strong></td>
<td>At the core of AGITG activity are our clinical trials. This session will present updates on ICECREAM, SCOT, ASCOLT, InterAACT, CO.23 and plans for our newest trials MONARCC, SPAR, and LIBERATE.</td>
</tr>
<tr>
<td>16:45 - 18:30</td>
<td><strong>New Concepts Symposium sponsored by Specialised Therapeutics Australia</strong></td>
<td>The New Concepts Symposium is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance. A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible.</td>
</tr>
<tr>
<td>18:30 - 20:00</td>
<td><strong>Welcome Reception</strong></td>
<td>Delegates will be welcomed to the 19th Annual Scientific Meeting in the Trade Hall after day one sessions have completed. This is a perfect opportunity to network with colleagues, discuss the next trial design, and enjoy the wines and delicious canapes prepared by the chef team at the Cairns Convention Centre utilising healthy and fresh produce from dedicated local growers in the pristine local environment.</td>
</tr>
</tbody>
</table>

We hope to see you in Cairns this October. www.agitg.org.au
# Keynote Breakfast presented
Professor John Reynolds will present on Obesity, Diabetes and Oesophageal Adenocarcinoma: Lessons from the Bench and the Bedside.

# AGITG/ANZGOSA Joint Plenary
This plenary session will involve three of our international invited speakers from the fields of medical; radiation and surgical oncology, this opening session will lay the foundation for cross discipline discussion that is a highlight of this meeting. The session will cover new management options for systemic chemotherapy with A/Prof Thierry Alcindor. New technology and methods to improve the therapeutic outcomes for patients undergoing radiotherapy for oesophageal cancer will be outlined by Prof Karyn Goodman. The impact of multimodal therapy on surgical outcomes and how to strive for the best outcome for our patients will be explored by Prof John Reynolds.

# Responding to response - Challenging the paradigm
This thought provoking session will consider the role of Molecular markers of prognosis and prediction presented by Prof Andrew Barbour; and Clinical and imaging predictors of response presented by Dr Ian Chau. Surgeon Dr Paul Cashin and radiation oncologist Prof Karyn Goodman will battle it out in the debate That complete clinical responders still require surgery for oesophageal cancer.

# Trial Session: Oesophagogastric Trials in Action
Central to aim of the AGITG-ANZGOSA combined day is fostering greater involvement in oesophagogastric trials. This session will present updates on AGITG trials TOPGEAR, DOCTOR and INTEGRATE II. Intrapertoneal Chemotherapy for Gastric Cancer will be discussed and Prof John Reynolds will present on Current European Trials: Rapid progress - forwards or backwards?

# The Super MDT
The aim of The Super MDT is for the Chairs, A/Prof Nick Pavlakis (AGITG) and Prof Mark Smithers (ANZGOSA), to present a selection of upper GI cases covering oesophago-gastric malignancy and areas of controversy. The role of the panel is to provide input and insights and to help develop robust discussion. The panel will comprise clinicians from each discipline:
- Surgery – Prof John Reynolds, Prof David Watson, Prof Mark Smithers
- Radiation Oncology – Prof Karyn Goodman, Prof Trevor Leong and Dr David Pryor
- Medical Oncology – A/Prof Thierry Alcindor, Dr Ian Chau and Dr Chris Jackson

# AGITG-ANZGOSA Combined Reception and Dinner
The AGITG-ANZGOSA Combined Reception will be held in the lush gardens of the Shangri-La Hotel, The Marina, Cairns. Delegates will enjoy waterfront dining at the conference dinner with lush mountain and sea views of Trinity Inlet and the famous Marlin Marina. Formalities will include presentation of the prestigious John Zalcberg OAM Award for Excellence in AGITG Research; announcements of the successful 2017 Innovation Fund project and Merck-AGITG Clinical Research Fellowship in GI Cancer; presentation of the Best of New Concepts Awards and AGITG Outstanding Site Award.

---

We hope to see you in Cairns this October. [Visit AGITG website](http://www.agitg.org.au)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Keynote Breakfast sponsored by Shire</td>
</tr>
<tr>
<td>8:00</td>
<td>Professor John Bridgewater will present New data, new standards: BILCAP and new EPOC. The New EPOC investigated whether the addition of cetuximab systemic chemotherapy in patients with resectable colorectal liver metastasis was of benefit to disease free survival. Unexpectedly, cetuximab appeared to adversely affect outcome. The mature survival data and translational analyses to date will be shown. The BILCAP study whether capecitabine improved overall survival compared to surveillance in patients following resection of biliary tract cancer. The outcome data will be presented, including cost economic and quality of life analyses.</td>
</tr>
<tr>
<td>8:00</td>
<td>Radiation Oncology Contouring Breakfast Workshop</td>
</tr>
<tr>
<td>8:00</td>
<td>The meeting program has been adjusted this year to be of particular interest to the radiation oncology community. We are incredibly fortunate to have at the meeting Prof Karyn Goodman who is very prominent in the RTOG GI community and regularly chairs RTOG GI contouring workshops. With her present, we have decided to create a half day contouring workshop on Friday 6th October where we will discuss our “art” and focus on anal, oesophageal and pancreas cancer. As well as covering conventional pancreatic treatment, we plan to explore pancreatic SBRT and produce AGITG guidelines for this as a prelude to possible AGITG trials. The meeting has many multidisciplinary sessions and will showcase all the gastro-intestinal studies on offer in Australia and New Zealand. We hope that it will be a rewarding few days to both consultants and registrars and encourage as many of our faculty to attend.</td>
</tr>
<tr>
<td>9:00</td>
<td>Trial Session: Hepatopancreatobiliary, GIST and NET</td>
</tr>
<tr>
<td>9:00</td>
<td>Updates will be presented by Principal Investigators on the ALT-GIST, ACTICCA-1, NABNEC, CONTROL NETS and NAB-CAPABIL trials.</td>
</tr>
<tr>
<td>10:45</td>
<td>Best of the Best/Fast Forward sponsored by Ipsen</td>
</tr>
<tr>
<td>10:45</td>
<td>The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee. Posters are displayed in the exhibition area. Four posters are chosen for presentation in the Best of Posters Session. Prizes are awarded for Best of Posters and Runner Up, both sponsored by Ipsen.</td>
</tr>
<tr>
<td>11:45</td>
<td>Closing Plenary sponsored by Roche</td>
</tr>
<tr>
<td>11:45</td>
<td>Implementation v Innovation – What rules in my world? With all the changes in oncology ‘hot off the press’, how do we go from concepts to implementation? This session will be presented by leaders in each field who will highlight the challenges and ‘quick wins’ in bringing advances through to the clinic.</td>
</tr>
<tr>
<td>13:15</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td>13:15</td>
<td>Meeting Convenor Professor Eva Segelov will wrap up the 19th AGITG Annual Scientific Meeting</td>
</tr>
<tr>
<td>14:15</td>
<td>Trainees Workshop</td>
</tr>
<tr>
<td>14:15</td>
<td>A career in oncology is highly rewarding and increasingly popular. An increasing number of trainees and a competitive job market means that now, more than ever, trainees need to be thoughtful and strategic about planning their training with an eye to the job market. This trainee’s workshop presents a unique opportunity to meet with senior and successful medical, surgical and radiation oncologists who have followed varied paths to their current position. This workshop will explore the many different opportunities available to trainees, and how to navigate training, research, service, teaching, fellowships, and how to flourish as a clinician, researcher, leader, teacher, or all four in Australia and New Zealand. Registration is essential as places are limited in this special session.</td>
</tr>
<tr>
<td>14:15</td>
<td>Joint Consumer / Study Coordinator Forum</td>
</tr>
<tr>
<td>14:15</td>
<td>The Joint Consumer / Study Coordinator Forum speakers cover a range of topics relevant in today’s treatment settings. The use of biomarkers in the treatment of GI cancer is evaluated, as well as current surgical options for oesophagogastric cancer. The interface between the study and the patient is the Study Coordinator. Showcased is a day, a snapshot, of the challenges and learnings of this role. Additionally, from the recognition obesity and diet has a part in maintaining health, these aspects are highlighted in pre and post treatment cancer treatments.</td>
</tr>
</tbody>
</table>

We hope to see you in Cairns this October. www.agitg.org.au
SPONSORS

Platinum Sponsor

AMGEN

Gold Sponsors

IPSEN
Roche
Shire
Merck

Silver Sponsors

Specialised Therapeutics Australia
Novartis

Bronze Sponsors

SIRTEX
Servier
Pfizer
Menarini
Bristol-Myers Squibb
Seqirus
Oncosil